RG3039
Product Specifications
UNSPSC Description
RG3039 (PF-06687859) is an orally bioavailable and brain-penetrant DcpS inhibitor with an IC50 of 0.069 nM.
Target Antigen
Others
Type
Reference compound
Related Pathways
Others
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/RG3039.html
Purity
99.62
Solubility
DMSO : 5 mg/mL (ultrasonic;warming;heat to 60°C)|H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C)
Smiles
NC1=NC(N)=C2C(OCC3CCN(CC4=C(Cl)C=CC=C4Cl)CC3)=CC=CC2=N1
Molecular Weight
432.35
References & Citations
[1]Gopalsamy A, et al. Design of Potent mRNA Decapping Scavenger Enzyme (DcpS) Inhibitors with Improved Physicochemical Properties To Investigate the Mechanism of Therapeutic Benefit in Spinal Muscular Atrophy (SMA). J Med Chem. 2017 Apr 13;60(7):3094-3108.|[2]Gogliotti RG, et al. The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models. Hum Mol Genet. 2013 Oct 15;22(20):4084-101.|[3]Van Meerbeke J, et al. The DcpS inhibitor RG3039 improves motor function in SMA mice. Hum Mol Genet. 2013 Oct 15;22(20):4074-83.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-102020/RG3039-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-102020/RG3039-SDS-MedChemExpress.pdf
Clinical Information
Phase 1
CAS Number
1005504-62-0
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1184580-01 0.02 mg (E-Coli)
Recombinant Fervidobacterium nodosum UDP-N-acetylglucosamine 1-carboxyvinyltransferase (murA)
Ask
View Details MBS1184580-02 0.02 mg (Yeast)
Recombinant Fervidobacterium nodosum UDP-N-acetylglucosamine 1-carboxyvinyltransferase (murA)
Ask
View Details MBS1184580-03 0.1 mg (E-Coli)
Recombinant Fervidobacterium nodosum UDP-N-acetylglucosamine 1-carboxyvinyltransferase (murA)
Ask
View Details